Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 10;35(26):3021-3029.
doi: 10.1200/JCO.2016.71.6183. Epub 2017 Aug 2.

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631

Matthew A Kutny  1 , Todd A Alonzo  1 , Robert B Gerbing  1 , Yi-Cheng Wang  1 , Susana C Raimondi  1 , Betsy A Hirsch  1 , Cecilia H Fu  1 , Soheil Meshinchi  1 , Alan S Gamis  1 , James H Feusner  1 , John J Gregory Jr  1
Affiliations
Clinical Trial

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631

Matthew A Kutny et al. J Clin Oncol. .

Abstract

Purpose The Children's Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. Patients and Methods Patients age 2 to 21 years with de novo APL confirmed by PML-RARα polymerase chain reaction were stratified as standard risk (SR) or high risk (HR) on the basis of diagnostic WBC count. All patients received all-trans retinoic acid (ATRA) during induction, each consolidation course, and maintenance. All patients received two cycles of ATO therapy during consolidation 1, an additional two (SR) or three (HR) consolidation courses that included high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine. Results One hundred one patients (66 SR and 35 HR) were evaluable for outcome. The 3-year overall survival was 94%, and event-free survival (EFS) was 91%. For SR and HR patients with APL, the overall survival was 98% versus 86% ( P = .003), and EFS was 95% versus 83% ( P = .03), respectively. The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 historical control, which used a significantly higher anthracycline dose and did not include ATO consolidation. Relapse risk for patients in AAML0631 from end consolidation 1 (after ATO treatment) was only 4% at 3 years and did not differ significantly between SR and HR patients. Conclusion ATO consolidation cycles were well tolerated in pediatric patients with APL and allowed significant reduction in cumulative anthracycline doses while maintaining excellent survival and a low relapse risk for both SR and HR patients with APL.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
CONSORT diagram for the study. HR, high risk; PCR, polymerase chain reaction; PML-RARα, promyelocytic leukemia and retinoic acid receptor alpha fusion gene; SR, standard risk.
Fig 2.
Fig 2.
Survival by risk group including (A) overall survival, (B) event-free survival, and (C) disease-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aldouri MA, Lopes ME, Yacoub M, et al. : Cardiac transplantation for doxorubicin-induced cardiomyopathy in acute myeloid leukaemia. Br J Haematol 74:541, 1990 - PubMed
    1. Thomas X, Le QH, Fiere D: Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol 81:504-507, 2002 - PubMed
    1. Shankar SM, Marina N, Hudson MM, et al. : Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 121:e387-e396, 2008 - PubMed
    1. Gregory J, Kim H, Alonzo T, et al. : Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 53:1005-1010, 2009 - PMC - PubMed
    1. Testi AM, Biondi A, Lo Coco F, et al. : GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106:447-453, 2005 - PubMed

Publication types

MeSH terms